Abstract
Various North American guidelines regarding prenatal screening for chlamydia and gonorrhea provide conflicting recommendations, and reflect differences in the values underlying interpretation of the available evidence. A systematic search of the literature was conducted to identify evidence regarding the risks and benefits of prenatal screening and treatment of chlamydia and gonorrhea. The available evidence suggests that there is an overall benefit to screening in both the first and third trimesters for women with risk factors for infection or for women living in settings with a high prevalence of infection. Women with no known risk factors who live in settings with a low prevalence of infection should be offered prenatal screening in the first trimester within a context of informed choice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian Journal of Midwifery Research and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
